drugset / Trial / NCT00061893

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of Ewing's sarcoma by stopping blood flow to the tumor. Combining more than one chemotherapy drug with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining low-dose vinblastine and celecoxib with standard regimens of combination chemotherapy in treating patients who have newly-diagnosed metastatic Ewing's sarcoma family of tumors.

Timeline

Start
2004-04
Primary completion
2008-04
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 250 mg/m2 Oral
Subject Vinblastine Small molecule 1 mg/m2 Intravenous
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 60 % Intravenous
Background Cyclophosphamide Other / unclassified 1200 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 75 mg/m2 Intravenous
Background Etoposide Small molecule Intravenous
Background Ifosfamide Small molecule 1800 mg/m2 Intravenous
Background Vincristine Small molecule 2 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous

Indications